Share Price and Basic Stock Data
Last Updated: November 22, 2025, 8:00 am
| PEG Ratio | 2.02 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Artemis Medicare Services Ltd operates in the Hospitals & Medical Services industry, with a current market capitalization of ₹4,546 Cr. The company reported a notable growth in revenues, with sales increasing from ₹545 Cr in FY 2022 to ₹714 Cr in FY 2023, and further projected to reach ₹845 Cr in FY 2024 and ₹913 Cr in FY 2025. The quarterly sales figures also highlight a consistent upward trajectory, rising from ₹163 Cr in June 2022 to ₹201 Cr in June 2023, and reaching ₹217 Cr in September 2023. This growth reflects Artemis’s ability to adapt to market demands and expand its service offerings. The operating profit margin (OPM) stood at 16% for FY 2025, showcasing an improvement from 12% in FY 2022, indicating enhanced operational efficiency. The company’s ability to generate revenues is supported by its strategic initiatives and investments aimed at bolstering healthcare services, which is crucial in a rapidly evolving healthcare landscape.
Profitability and Efficiency Metrics
Artemis Medicare’s profitability metrics reveal a strong operational performance, with net profits rising from ₹33 Cr in FY 2022 to ₹40 Cr in FY 2023, and projected at ₹49 Cr in FY 2024 and ₹83 Cr in FY 2025. The earnings per share (EPS) has shown significant growth, increasing from ₹2.46 in FY 2022 to ₹2.96 in FY 2023, and expected to reach ₹6.07 in FY 2025. The company reported a return on equity (ROE) of 12.9% and a return on capital employed (ROCE) of 14.9%, both of which are indicative of efficient capital utilization. The interest coverage ratio (ICR) stood at 5.78x, reflecting a strong capacity to meet interest obligations. However, the company faces challenges with a high price-to-earnings (P/E) ratio of 47.7, suggesting that the stock may be overvalued relative to earnings, which could pose risks if earnings growth does not keep pace with market expectations.
Balance Sheet Strength and Financial Ratios
The balance sheet of Artemis Medicare Services demonstrates a solid financial position, with total assets reaching ₹1,343 Cr in FY 2025, up from ₹882 Cr in FY 2023. The company’s reserves have also significantly increased to ₹828 Cr, indicating strong retained earnings and a commitment to reinvest in future growth. Total borrowings stood at ₹280 Cr, reflecting a manageable debt level, particularly given the company’s interest coverage ratio of 5.78x. The current ratio of 2.49x indicates a robust liquidity position, allowing the company to meet short-term obligations comfortably. However, the debt-to-equity ratio of 0.31x suggests that while the company is leveraging debt to fuel growth, it remains relatively conservative compared to industry norms. This balance between leveraging growth and maintaining financial stability is critical for sustaining long-term operational success.
Shareholding Pattern and Investor Confidence
Artemis Medicare’s shareholding pattern is characterized by a significant promoter holding of 66.53%, reflecting strong insider confidence in the company’s future prospects. The presence of foreign institutional investors (FIIs) is minimal at 0.37%, while domestic institutional investors (DIIs) account for 4.27%, indicating a cautious approach from institutional investors towards this stock. The company has seen a steady increase in the number of shareholders, rising from 17,995 in December 2022 to 33,559 by September 2025, which signifies growing retail interest. The declining trend in promoter holding from 68.91% in December 2022 to 66.53% in June 2025 may raise concerns about potential dilution of control, but the overall stability in shareholding suggests a relatively sound investor sentiment. This pattern could influence future capital-raising strategies and shareholder engagement initiatives.
Outlook, Risks, and Final Insight
The outlook for Artemis Medicare Services appears positive, driven by strong revenue growth and improved profitability metrics. However, the high P/E ratio and increasing operational costs pose significant risks that could impact future performance. The healthcare sector’s dynamics, including regulatory changes and competition, could also affect the company’s growth trajectory. The company must navigate these challenges while leveraging its robust balance sheet and operational efficiencies to maintain investor confidence. To sustain growth, Artemis may consider diversifying its service offerings and enhancing patient engagement strategies. Overall, if Artemis can effectively manage its risks and capitalize on emerging opportunities in the healthcare sector, it is well-positioned for continued growth and shareholder value creation.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Artemis Medicare Services Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 46.4 Cr. | 139 | 195/125 | 9.48 | 117 | 2.53 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 21.2 Cr. | 20.2 | 35.5/18.3 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 12.0 Cr. | 11.6 | 21.4/11.6 | 133 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 121 Cr. | 64.3 | 98.7/53.1 | 26.6 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 21.5 Cr. | 3.98 | 7.60/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 27,996.36 Cr | 842.13 | 101.54 | 102.21 | 0.27% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 163 | 182 | 181 | 187 | 201 | 217 | 210 | 217 | 217 | 235 | 227 | 235 | 250 |
| Expenses | 144 | 158 | 156 | 163 | 174 | 184 | 179 | 181 | 181 | 193 | 190 | 199 | 209 |
| Operating Profit | 19 | 24 | 26 | 25 | 27 | 33 | 32 | 36 | 36 | 42 | 37 | 36 | 41 |
| OPM % | 12% | 13% | 14% | 13% | 14% | 15% | 15% | 17% | 16% | 18% | 16% | 15% | 16% |
| Other Income | 2 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 4 | 8 | 9 | 12 | 7 |
| Interest | 4 | 5 | 5 | 5 | 6 | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 7 |
| Depreciation | 6 | 7 | 8 | 8 | 9 | 9 | 10 | 10 | 10 | 11 | 11 | 11 | 11 |
| Profit before tax | 11 | 14 | 14 | 14 | 13 | 19 | 16 | 19 | 22 | 31 | 27 | 29 | 30 |
| Tax % | 22% | 31% | 23% | 23% | 26% | 27% | 29% | 28% | 24% | 27% | 23% | 20% | 29% |
| Net Profit | 9 | 10 | 11 | 10 | 10 | 14 | 12 | 14 | 17 | 23 | 21 | 23 | 21 |
| EPS in Rs | 0.65 | 0.73 | 0.80 | 0.78 | 0.73 | 1.01 | 0.85 | 1.02 | 1.24 | 1.64 | 1.51 | 1.69 | 1.54 |
Last Updated: August 20, 2025, 1:35 pm
Below is a detailed analysis of the quarterly data for Artemis Medicare Services Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 250.00 Cr.. The value appears strong and on an upward trend. It has increased from 235.00 Cr. (Mar 2025) to 250.00 Cr., marking an increase of 15.00 Cr..
- For Expenses, as of Jun 2025, the value is 209.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 199.00 Cr. (Mar 2025) to 209.00 Cr., marking an increase of 10.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 5.00 Cr..
- For OPM %, as of Jun 2025, the value is 16.00%. The value appears strong and on an upward trend. It has increased from 15.00% (Mar 2025) to 16.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 5.00 Cr..
- For Interest, as of Jun 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 11.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 30.00 Cr.. The value appears strong and on an upward trend. It has increased from 29.00 Cr. (Mar 2025) to 30.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Jun 2025, the value is 29.00%. The value appears to be increasing, which may not be favorable. It has increased from 20.00% (Mar 2025) to 29.00%, marking an increase of 9.00%.
- For Net Profit, as of Jun 2025, the value is 21.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Mar 2025) to 21.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.54. The value appears to be declining and may need further review. It has decreased from 1.69 (Mar 2025) to 1.54, marking a decrease of 0.15.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:44 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 261 | 368 | 402 | 459 | 503 | 547 | 563 | 402 | 545 | 714 | 845 | 913 | 981 |
| Expenses | 234 | 325 | 359 | 406 | 442 | 480 | 501 | 367 | 477 | 620 | 717 | 763 | 818 |
| Operating Profit | 27 | 43 | 43 | 53 | 60 | 66 | 62 | 35 | 68 | 94 | 128 | 150 | 163 |
| OPM % | 11% | 12% | 11% | 11% | 12% | 12% | 11% | 9% | 12% | 13% | 15% | 16% | 17% |
| Other Income | 1 | 3 | 5 | 4 | 3 | 2 | 4 | 7 | 3 | 7 | 7 | 33 | 36 |
| Interest | 13 | 12 | 9 | 9 | 9 | 11 | 13 | 12 | 11 | 19 | 30 | 30 | 29 |
| Depreciation | 9 | 12 | 12 | 15 | 18 | 20 | 22 | 21 | 21 | 29 | 38 | 43 | 44 |
| Profit before tax | 7 | 21 | 27 | 32 | 35 | 37 | 32 | 9 | 39 | 53 | 68 | 109 | 126 |
| Tax % | 0% | 12% | 21% | 16% | 24% | 44% | 36% | 20% | 16% | 25% | 28% | 24% | |
| Net Profit | 7 | 19 | 22 | 27 | 27 | 21 | 20 | 7 | 33 | 40 | 49 | 83 | 95 |
| EPS in Rs | 0.32 | 0.88 | 1.03 | 1.29 | 1.27 | 0.98 | 1.54 | 0.54 | 2.46 | 2.96 | 3.62 | 6.07 | 6.90 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 15% | 12% | 7% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 171.43% | 15.79% | 22.73% | 0.00% | -22.22% | -4.76% | -65.00% | 371.43% | 21.21% | 22.50% | 69.39% |
| Change in YoY Net Profit Growth (%) | 0.00% | -155.64% | 6.94% | -22.73% | -22.22% | 17.46% | -60.24% | 436.43% | -350.22% | 1.29% | 46.89% |
Artemis Medicare Services Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 10% |
| 3 Years: | 19% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 32% |
| 3 Years: | 36% |
| TTM: | 57% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 69% |
| 3 Years: | 53% |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 10% |
| 3 Years: | 12% |
| Last Year: | 13% |
Last Updated: September 4, 2025, 11:40 pm
Balance Sheet
Last Updated: July 25, 2025, 3:35 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 0.00 | 13 | 13 | 13 | 13 | 14 | 14 |
| Reserves | 116 | 135 | 163 | 183 | 210 | 280 | 301 | 308 | 348 | 393 | 438 | 828 |
| Borrowings | 110 | 85 | 68 | 94 | 91 | 114 | 108 | 137 | 190 | 268 | 305 | 280 |
| Other Liabilities | 66 | 90 | 93 | 124 | 130 | 160 | 159 | 130 | 145 | 207 | 191 | 221 |
| Total Liabilities | 313 | 331 | 345 | 422 | 452 | 555 | 581 | 589 | 697 | 882 | 948 | 1,343 |
| Fixed Assets | 236 | 239 | 249 | 283 | 309 | 381 | 387 | 372 | 476 | 584 | 699 | 729 |
| CWIP | 0 | 0 | 1 | 27 | 43 | 49 | 56 | 81 | 64 | 95 | 33 | 40 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 6 | 12 | 15 | 15 |
| Other Assets | 77 | 91 | 94 | 112 | 100 | 124 | 137 | 132 | 152 | 192 | 200 | 559 |
| Total Assets | 313 | 331 | 345 | 422 | 452 | 555 | 581 | 589 | 697 | 882 | 948 | 1,343 |
Below is a detailed analysis of the balance sheet data for Artemis Medicare Services Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.00 Cr..
- For Reserves, as of Mar 2025, the value is 828.00 Cr.. The value appears strong and on an upward trend. It has increased from 438.00 Cr. (Mar 2024) to 828.00 Cr., marking an increase of 390.00 Cr..
- For Borrowings, as of Mar 2025, the value is 280.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 305.00 Cr. (Mar 2024) to 280.00 Cr., marking a decrease of 25.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 221.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 191.00 Cr. (Mar 2024) to 221.00 Cr., marking an increase of 30.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,343.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 948.00 Cr. (Mar 2024) to 1,343.00 Cr., marking an increase of 395.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 729.00 Cr.. The value appears strong and on an upward trend. It has increased from 699.00 Cr. (Mar 2024) to 729.00 Cr., marking an increase of 30.00 Cr..
- For CWIP, as of Mar 2025, the value is 40.00 Cr.. The value appears strong and on an upward trend. It has increased from 33.00 Cr. (Mar 2024) to 40.00 Cr., marking an increase of 7.00 Cr..
- For Investments, as of Mar 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 15.00 Cr..
- For Other Assets, as of Mar 2025, the value is 559.00 Cr.. The value appears strong and on an upward trend. It has increased from 200.00 Cr. (Mar 2024) to 559.00 Cr., marking an increase of 359.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,343.00 Cr.. The value appears strong and on an upward trend. It has increased from 948.00 Cr. (Mar 2024) to 1,343.00 Cr., marking an increase of 395.00 Cr..
Notably, the Reserves (828.00 Cr.) exceed the Borrowings (280.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -83.00 | -42.00 | -25.00 | -41.00 | -31.00 | -48.00 | -46.00 | -102.00 | -122.00 | -174.00 | -177.00 | -130.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 41 | 39 | 49 | 48 | 40 | 52 | 50 | 48 | 47 | 43 | 36 | 37 |
| Inventory Days | 26 | 26 | 21 | 19 | ||||||||
| Days Payable | 237 | 195 | 189 | 187 | ||||||||
| Cash Conversion Cycle | -171 | -129 | -120 | -120 | 40 | 52 | 50 | 48 | 47 | 43 | 36 | 37 |
| Working Capital Days | -70 | -59 | -31 | -44 | -53 | -51 | -36 | -35 | -25 | -45 | -29 | -29 |
| ROCE % | 8% | 14% | 15% | 16% | 15% | 14% | 11% | 4% | 10% | 11% | 14% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Bandhan Small Cap Fund | 421,079 | 0.15 | 7.68 | 421,079 | 2025-04-22 17:25:42 | 0% |
| LIC MF Focused Fund | 205,202 | 2.83 | 3.74 | 205,202 | 2025-04-22 17:25:42 | 0% |
| LIC MF Healthcare Fund | 156,172 | 4.58 | 2.85 | 156,172 | 2025-04-22 17:25:42 | 0% |
| LIC MF Small Cap Fund | 122,701 | 1 | 2.24 | 122,701 | 2025-04-22 17:25:42 | 0% |
| LIC MF Dividend Yield Fund | 79,326 | 0.95 | 1.45 | 79,326 | 2025-04-22 15:57:00 | 0% |
| LIC MF Value Fund | 76,393 | 1.27 | 1.39 | 76,393 | 2025-04-22 15:57:00 | 0% |
| Bandhan Midcap Fund | 70,016 | 0.11 | 1.28 | 70,016 | 2025-04-22 15:57:00 | 0% |
| LIC MF Equity Savings Fund | 3,888 | 0.45 | 0.07 | 3,888 | 2025-04-22 17:25:42 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 407 | 0.06 | 0.01 | 407 | 2025-04-22 17:25:42 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 10.00 |
| Basic EPS (Rs.) | 5.37 | 3.62 | 2.89 | 2.40 | 4.90 |
| Diluted EPS (Rs.) | 5.31 | 3.53 | 2.79 | 2.29 | 4.90 |
| Cash EPS (Rs.) | 9.25 | 6.58 | 5.15 | 4.05 | 20.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 55.90 | 28.46 | 25.37 | 22.23 | 243.05 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 60.88 | 33.47 | 30.40 | 27.29 | 243.05 |
| Revenue From Operations / Share (Rs.) | 68.09 | 64.67 | 54.98 | 41.91 | 308.51 |
| PBDIT / Share (Rs.) | 13.43 | 10.31 | 7.55 | 5.39 | 29.26 |
| PBIT / Share (Rs.) | 10.15 | 7.34 | 5.24 | 3.71 | 13.01 |
| PBT / Share (Rs.) | 7.82 | 5.04 | 3.77 | 2.81 | 5.69 |
| Net Profit / Share (Rs.) | 5.97 | 3.62 | 2.83 | 2.37 | 4.65 |
| NP After MI And SOA / Share (Rs.) | 6.00 | 3.62 | 2.88 | 2.40 | 4.90 |
| PBDIT Margin (%) | 19.72 | 15.94 | 13.73 | 12.86 | 9.48 |
| PBIT Margin (%) | 14.90 | 11.35 | 9.53 | 8.86 | 4.21 |
| PBT Margin (%) | 11.49 | 7.79 | 6.86 | 6.70 | 1.84 |
| Net Profit Margin (%) | 8.77 | 5.59 | 5.15 | 5.65 | 1.50 |
| NP After MI And SOA Margin (%) | 8.81 | 5.59 | 5.23 | 5.73 | 1.58 |
| Return on Networth / Equity (%) | 10.74 | 12.91 | 11.49 | 10.87 | 2.02 |
| Return on Capital Employeed (%) | 12.23 | 12.67 | 10.05 | 8.60 | 3.57 |
| Return On Assets (%) | 6.08 | 5.05 | 4.26 | 4.48 | 1.08 |
| Long Term Debt / Equity (X) | 0.27 | 0.59 | 0.63 | 0.55 | 0.33 |
| Total Debt / Equity (X) | 0.31 | 0.66 | 0.71 | 0.62 | 0.33 |
| Asset Turnover Ratio (%) | 0.80 | 0.93 | 0.89 | 0.83 | 0.68 |
| Current Ratio (X) | 2.49 | 0.97 | 0.82 | 0.91 | 0.92 |
| Quick Ratio (X) | 2.45 | 0.92 | 0.75 | 0.82 | 0.84 |
| Inventory Turnover Ratio (X) | 93.21 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 7.45 | 12.44 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 4.82 | 6.83 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 92.55 | 87.56 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 95.18 | 93.17 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 5.78 | 4.48 | 5.15 | 5.96 | 3.00 |
| Interest Coverage Ratio (Post Tax) (X) | 3.57 | 2.57 | 2.93 | 3.62 | 1.23 |
| Enterprise Value (Cr.) | 3636.78 | 2505.47 | 1107.95 | 765.31 | 372.04 |
| EV / Net Operating Revenue (X) | 3.88 | 2.85 | 1.50 | 1.38 | 0.91 |
| EV / EBITDA (X) | 19.68 | 17.89 | 10.94 | 10.73 | 9.60 |
| MarketCap / Net Operating Revenue (X) | 4.04 | 2.63 | 1.24 | 1.10 | 0.71 |
| Retention Ratios (%) | 92.54 | 87.55 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 4.92 | 6.06 | 2.72 | 2.08 | 0.91 |
| Price / Net Operating Revenue (X) | 4.04 | 2.63 | 1.24 | 1.10 | 0.71 |
| EarningsYield | 0.02 | 0.02 | 0.04 | 0.05 | 0.02 |
After reviewing the key financial ratios for Artemis Medicare Services Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 3.62 (Mar 24) to 5.37, marking an increase of 1.75.
- For Diluted EPS (Rs.), as of Mar 25, the value is 5.31. This value is within the healthy range. It has increased from 3.53 (Mar 24) to 5.31, marking an increase of 1.78.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.25. This value is within the healthy range. It has increased from 6.58 (Mar 24) to 9.25, marking an increase of 2.67.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 55.90. It has increased from 28.46 (Mar 24) to 55.90, marking an increase of 27.44.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.88. It has increased from 33.47 (Mar 24) to 60.88, marking an increase of 27.41.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 68.09. It has increased from 64.67 (Mar 24) to 68.09, marking an increase of 3.42.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.43. This value is within the healthy range. It has increased from 10.31 (Mar 24) to 13.43, marking an increase of 3.12.
- For PBIT / Share (Rs.), as of Mar 25, the value is 10.15. This value is within the healthy range. It has increased from 7.34 (Mar 24) to 10.15, marking an increase of 2.81.
- For PBT / Share (Rs.), as of Mar 25, the value is 7.82. This value is within the healthy range. It has increased from 5.04 (Mar 24) to 7.82, marking an increase of 2.78.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 5.97. This value is within the healthy range. It has increased from 3.62 (Mar 24) to 5.97, marking an increase of 2.35.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 6.00. This value is within the healthy range. It has increased from 3.62 (Mar 24) to 6.00, marking an increase of 2.38.
- For PBDIT Margin (%), as of Mar 25, the value is 19.72. This value is within the healthy range. It has increased from 15.94 (Mar 24) to 19.72, marking an increase of 3.78.
- For PBIT Margin (%), as of Mar 25, the value is 14.90. This value is within the healthy range. It has increased from 11.35 (Mar 24) to 14.90, marking an increase of 3.55.
- For PBT Margin (%), as of Mar 25, the value is 11.49. This value is within the healthy range. It has increased from 7.79 (Mar 24) to 11.49, marking an increase of 3.70.
- For Net Profit Margin (%), as of Mar 25, the value is 8.77. This value is within the healthy range. It has increased from 5.59 (Mar 24) to 8.77, marking an increase of 3.18.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.81. This value is within the healthy range. It has increased from 5.59 (Mar 24) to 8.81, marking an increase of 3.22.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.74. This value is below the healthy minimum of 15. It has decreased from 12.91 (Mar 24) to 10.74, marking a decrease of 2.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.23. This value is within the healthy range. It has decreased from 12.67 (Mar 24) to 12.23, marking a decrease of 0.44.
- For Return On Assets (%), as of Mar 25, the value is 6.08. This value is within the healthy range. It has increased from 5.05 (Mar 24) to 6.08, marking an increase of 1.03.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.27. This value is within the healthy range. It has decreased from 0.59 (Mar 24) to 0.27, marking a decrease of 0.32.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.31. This value is within the healthy range. It has decreased from 0.66 (Mar 24) to 0.31, marking a decrease of 0.35.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.80. It has decreased from 0.93 (Mar 24) to 0.80, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 2.49. This value is within the healthy range. It has increased from 0.97 (Mar 24) to 2.49, marking an increase of 1.52.
- For Quick Ratio (X), as of Mar 25, the value is 2.45. This value exceeds the healthy maximum of 2. It has increased from 0.92 (Mar 24) to 2.45, marking an increase of 1.53.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 93.21. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 93.21, marking an increase of 93.21.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 7.45. This value is below the healthy minimum of 20. It has decreased from 12.44 (Mar 24) to 7.45, marking a decrease of 4.99.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.82. This value is below the healthy minimum of 20. It has decreased from 6.83 (Mar 24) to 4.82, marking a decrease of 2.01.
- For Earning Retention Ratio (%), as of Mar 25, the value is 92.55. This value exceeds the healthy maximum of 70. It has increased from 87.56 (Mar 24) to 92.55, marking an increase of 4.99.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.18. This value exceeds the healthy maximum of 70. It has increased from 93.17 (Mar 24) to 95.18, marking an increase of 2.01.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.78. This value is within the healthy range. It has increased from 4.48 (Mar 24) to 5.78, marking an increase of 1.30.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.57. This value is within the healthy range. It has increased from 2.57 (Mar 24) to 3.57, marking an increase of 1.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,636.78. It has increased from 2,505.47 (Mar 24) to 3,636.78, marking an increase of 1,131.31.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has increased from 2.85 (Mar 24) to 3.88, marking an increase of 1.03.
- For EV / EBITDA (X), as of Mar 25, the value is 19.68. This value exceeds the healthy maximum of 15. It has increased from 17.89 (Mar 24) to 19.68, marking an increase of 1.79.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has increased from 2.63 (Mar 24) to 4.04, marking an increase of 1.41.
- For Retention Ratios (%), as of Mar 25, the value is 92.54. This value exceeds the healthy maximum of 70. It has increased from 87.55 (Mar 24) to 92.54, marking an increase of 4.99.
- For Price / BV (X), as of Mar 25, the value is 4.92. This value exceeds the healthy maximum of 3. It has decreased from 6.06 (Mar 24) to 4.92, marking a decrease of 1.14.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has increased from 2.63 (Mar 24) to 4.04, marking an increase of 1.41.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Artemis Medicare Services Ltd:
- Net Profit Margin: 8.77%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.23% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.74% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.57
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.45
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 46.2 (Industry average Stock P/E: 101.54)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.31
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.77%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Plot No. 14, Delhi Delhi 110075 | investor@artemishospitals.com http://www.artemishospitals.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Onkar Kanwar | Chairman & Non-Exe.Director |
| Dr.(Mrs.) Devlina Chakravarty | Managing Director |
| Mr. Neeraj Kanwar | Non Executive Director |
| Mrs. Shalini Kanwar Chand | Non Executive Director |
| Mr. Sunam Sarkar | Non Executive Director |
| Ms. Deepa Gopalan Wadhwa | Independent Director |
| Mr. Sunil Tandon | Independent Director |
| Mr. Sanjib Sen | Independent Director |
| Mr. Vinod Rai | Independent Director |
| Mr. Akshaykumar Narendrasinhji Chudasama | Independent Director |
| Ms. Pallavi Shardul Shroff | Independent Director |
FAQ
What is the intrinsic value of Artemis Medicare Services Ltd?
Artemis Medicare Services Ltd's intrinsic value (as of 25 November 2025) is 304.67 which is 9.59% higher the current market price of 278.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 4,405 Cr. market cap, FY2025-2026 high/low of 350/208, reserves of ₹828 Cr, and liabilities of 1,343 Cr.
What is the Market Cap of Artemis Medicare Services Ltd?
The Market Cap of Artemis Medicare Services Ltd is 4,405 Cr..
What is the current Stock Price of Artemis Medicare Services Ltd as on 25 November 2025?
The current stock price of Artemis Medicare Services Ltd as on 25 November 2025 is 278.
What is the High / Low of Artemis Medicare Services Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Artemis Medicare Services Ltd stocks is 350/208.
What is the Stock P/E of Artemis Medicare Services Ltd?
The Stock P/E of Artemis Medicare Services Ltd is 46.2.
What is the Book Value of Artemis Medicare Services Ltd?
The Book Value of Artemis Medicare Services Ltd is 63.8.
What is the Dividend Yield of Artemis Medicare Services Ltd?
The Dividend Yield of Artemis Medicare Services Ltd is 0.16 %.
What is the ROCE of Artemis Medicare Services Ltd?
The ROCE of Artemis Medicare Services Ltd is 14.9 %.
What is the ROE of Artemis Medicare Services Ltd?
The ROE of Artemis Medicare Services Ltd is 12.9 %.
What is the Face Value of Artemis Medicare Services Ltd?
The Face Value of Artemis Medicare Services Ltd is 1.00.